Data presented at the 36th Annual Society for Immunotherapy of Cancer (SITC) MeetingNANTES, France, Nov. 16, 2021 (GLOBE NEWSWIRE) -- November 16, 2021, 7:30 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented new clinical and translational data on Tedopi® (neoepitope-based cancer vaccine) in non-small cell lung cancer and the latest data from BiCKI®-IL-7 . OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. NANTES, France, March 09, 2022--Boehringer Ingelheim and OSE Immuno To Present Biomarker Analyses from the Phase 1 Clinical Trial with First-in-Class SIRPα Inhibitor BI 765063 Business Wire • 3. Poster une analyse Demander une analyse IA Analyse Lutessia Lutessia Opportunities. Its balanced. OSE-127 (monoclonal antibody targeting the CD127 receptor, the alpha chain of the interleukin-7 receptor) is partnered with Servier under an option agreement up to the completion of a Phase 2 clinical trial planned in autoimmune bowel diseases; in parallel, Servier plans a development in the Sjögren syndrome. OSE Immunotherapeutics Sylvie Détry sylvie.detry@ose-immuno.com +33 153 198 757 Investor Relations Thomas Guillot thomas.guillot@ose-immuno.com +33 607 380 431 Regulatory News: OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE) annonce la mise en ligne des documents préparatoires à l'Assemblée . OSE Immunotherapeutics Presented New Translational Data on Tedopi and ... The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. OSE Immunotherapeutics Announces Four Poster Presentations of ...
Barbara Pravi Album,
Le Figaro Anciens Numéros,
Pistachier Lentisque Culture,
Articles A
